Activated Immunostimulatory Cell Composition and Uses Thereof
OwnerIrene Ginis, Alan Smith +3inventors
InventorsIrene Ginis, Alan Smith, Adi Zuloff-Shani, Marina Bubis, Mitchell Shirvan
Life of this patent
Estimating the term…
Abstract
Methods of making activated immunostimulatory cell compositions, activated immunostimulatory cell compositions, and methods of using those compositions to stimulate therapeutic immune responses to tumors are described.
Claims25
A method for making an activated immunostimulatory cell composition, comprising:
- a) incubating human leukocytes under conditions of time and temperature to activate the leukocytes;
- b) subjecting the activated leukocytes to hypo osmotic shock;
- c) adding to the leukocytes a salt solution in an amount effective to restore isotonicity;
- d) mixing the leukocytes with a supportive medium;
- and
- e) incubating the leukocytes in the supportive medium for a period of time to at least induce maturation of dendritic cells, thereby making an activated immunostimulatory composition.
A method of making an activated immunostimulatory cell composition comprising incubating non-quiescent leukocytes in a supportive medium under conditions of time and temperature that induce maturation of dendritic cells, thereby making an activated immunostimulatory composition.
A method for making a composition comprising mature dendritic cells comprising:
- a) providing leukocytes,
- b) allowing the leukocytes to transition from a quiescent to an active state by maintaining the leukocytes at room temperature for about 8 to 20 hours,
- c) subjecting the leukocytes to hypo-osmotic shock, and
- d) incubating the shocked leukocytes for 36 hours to 14 days in a supportive medium to thereby make a composition comprising mature dendritic cells.
(canceled)
7-11. (canceled)
13-17. (canceled)
A composition comprising mature dendritic cells, activated helper T cells, cytolytic T cells, and at least one other leukocyte cell type.
22-26. (canceled)
A method of stabilizing or regressing a tumor in a patient comprising:
- a) collecting leukocytes from a patient afflicted with the tumor;
- b) culturing the leukocytes at about 37° C. in a supportive medium that contains antigens from the patient's tumor but lacks exogenously added cytokines or growth factors to form mature dendritic cells and activated lymphocytes;
- and
- c) administering a therapeutically effective amount of the composition to the patient.
(canceled)
Dependencies are inferred from the claim text.